COMPASS Pathways
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Established
- 2016-06-13
- Employees
- 186
- Market Cap
- -
- Introduction
Compass Pathways Plc is an investment holding company. It operates through its subsidiaries which provide mental health care services. The company was founded by Goldsmith George Jay and Malievaskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.
A Phase II, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of COMP360 in Participants With Recurrent Major Depressive Disorder
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 102
- Registration Number
- NCT05733546
- Locations
- 🇺🇸
Clinical Neuroscience Solutions Inc, Jacksonville, Florida, United States
🇺🇸Kadima Neuropsychiatry Institute, La Jolla, California, United States
🇺🇸Aims Trial, Plano, Texas, United States
Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD
- First Posted Date
- 2023-02-03
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 568
- Registration Number
- NCT05711940
- Locations
- 🇺🇸
Clinical Innovations, Inc., Bellflower, California, United States
🇺🇸Catalina Research Institute, LLC, Montclair, California, United States
🇺🇸CITrials, Riverside, California, United States
Efficacy, Safety, and Tolerability of COMP360 in Participants With TRD
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 255
- Registration Number
- NCT05624268
- Locations
- 🇺🇸
University of Arizona College of Medicine - Tuscon, Tucson, Arizona, United States
🇺🇸ProScience Research Group, Culver City, California, United States
🇺🇸Collaborative Neuroscience Network, LLC, Garden Grove, California, United States
Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 32
- Registration Number
- NCT05481736
- Locations
- 🇺🇸
Altman Clinical and Translational Research Institute, San Diego, California, United States
🇺🇸Sheppard Pratt Health System, Baltimore, Maryland, United States
🇺🇸Dell Medical School, Austin, Texas, United States
The Safety and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder
- First Posted Date
- 2022-04-05
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 22
- Registration Number
- NCT05312151
- Locations
- 🇺🇸
Sunstone Therapies, Rockville, Maryland, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
🇬🇧Kings College London, Institute of Psychiatry, Psychology and Neurology, London, United Kingdom
The Safety and Efficacy Of Psilocybin as an Adjunctive Therapy in Participants With Treatment Resistant Depression
- First Posted Date
- 2021-02-05
- Last Posted Date
- 2023-11-09
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 19
- Registration Number
- NCT04739865
- Locations
- 🇮🇪
Sheaf House, Tallaght Hospital, Dublin, Ireland
🇺🇸Kadima Neuropsychiatry Institute, La Jolla, California, United States
Long Term Follow Up Study to COMP 001 And COMP 003 Trials (P-TRD LTFU)
- Conditions
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2022-09-22
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 66
- Registration Number
- NCT04519957
- Locations
- 🇺🇸
Mood and Anxiety Disorders Program Emory University School of Medicine, Atlanta, Georgia, United States
🇺🇸UT Center of Excellence on Mood Disorders, University of Texas Health Science Center, Houston, Texas, United States
🇳🇱Groningen University Medical Centre, Groningen, Netherlands
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression
- First Posted Date
- 2018-12-13
- Last Posted Date
- 2023-04-24
- Lead Sponsor
- COMPASS Pathways
- Target Recruit Count
- 233
- Registration Number
- NCT03775200
- Locations
- 🇺🇸
Kadima Neuropsychiatry Institute, La Jolla, California, United States
🇺🇸Altman Clinical and Translational Research Institute, University of California, San Diego, California, United States
🇺🇸Stanford Department of Psychiatry, Stanford, California, United States